- Home
- RDN vs KNSA Comparison
RDN vs KNSA Comparison
Compare RDN & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RDN | KNSA |
|---|---|---|
| Founded | 1977 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.9B |
| IPO Year | 2008 | 2018 |
Fundamental Metrics
Financial Performance| Metric | RDN | KNSA |
|---|---|---|
| Price | $34.88 | $77.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $40.67 | ★ $60.86 |
| AVG Volume (30 Days) | ★ 903.3K | 415.4K |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | ★ 2.73% | N/A |
| EPS Growth | 5.61 | ★ 225.00 |
| EPS | ★ 1.74 | 0.27 |
| Revenue | ★ $1,197,084,000.00 | $677,564,000.00 |
| Revenue This Year | N/A | $37.48 |
| Revenue Next Year | $2.66 | $17.87 |
| P/E Ratio | ★ $20.00 | $293.81 |
| Revenue Growth | N/A | ★ 60.09 |
| 52 Week Low | $31.50 | $35.33 |
| 52 Week High | $41.05 | $82.94 |
Technical Indicators
Market Signals| Indicator | RDN | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 35.65 | 54.16 |
| Support Level | $31.87 | $44.95 |
| Resistance Level | $37.34 | $81.97 |
| Average True Range (ATR) | 0.68 | 2.39 |
| MACD | -0.12 | -0.39 |
| Stochastic Oscillator | 22.87 | 56.80 |
Price Performance
Historical ComparisonAbout RDN Radian Group Inc.
Radian Group Inc is engaged in mortgage and real estate services. It provides both credit-related mortgage insurance coverage and other products and services across the residential real estate and mortgage finance industries. It has one reportable segment, Mortgage Insurance, which primarily derives its revenue by providing private mortgage insurance on residential first-lien mortgage loans to mortgage lending institutions and mortgage credit investors.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.